The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A new validated staging system for AL amyloidosis: identifying ultra-high-risk disease
Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, shares insights into a novel staging system for patients with systemic light chain (AL) amyloidosis that aims to identify those with ultra-high-risk disease who may benefit from alternative treatment approaches. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
